• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.

作者信息

Niu Jiahua, Qiu Huiying, Xiang Fang, Zhu Lin, Yang Jun, Huang Chongmei, Zhou Kun, Tong Yin, Cai Yu, Dong Baoxia, Lu Yuan, Sun Xuedong, Wan Liping, Ding Xueying, Wang Haopeng, Song Xianmin

机构信息

Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Engineering Technology Research Center of Cell Therapy and Clinical Translation, Shanghai Science and Technology Committee (STCSM), Shanghai, China.

出版信息

Blood Cancer J. 2023 Mar 24;13(1):44. doi: 10.1038/s41408-023-00813-x.

DOI:10.1038/s41408-023-00813-x
PMID:36964132
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10039051/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d8/10039051/7a0112d00925/41408_2023_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d8/10039051/7a0112d00925/41408_2023_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d8/10039051/7a0112d00925/41408_2023_813_Fig1_HTML.jpg

相似文献

1
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.用于微小残留病阳性成人B细胞急性淋巴细胞白血病的CD19/CD22双特异性嵌合抗原受体T细胞：一项I期临床研究。
Blood Cancer J. 2023 Mar 24;13(1):44. doi: 10.1038/s41408-023-00813-x.
2
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.双特异性 CAR-T 细胞靶向 CD19 和 CD22 治疗复发或难治性 B 细胞急性淋巴细胞白血病成人患者。
J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8.
3
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.CD19 嵌合抗原受体 T 细胞治疗后复发的儿童 B 细胞急性淋巴细胞白血病中 CD19 和 CD22 嵌合抗原受体 T 细胞联合给药的安全性和有效性。
J Transl Med. 2023 Mar 22;21(1):213. doi: 10.1186/s12967-023-04019-4.
4
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.复发/难治性急性淋巴细胞白血病患者中CD19单特异性和CD19/CD22双特异性靶向嵌合抗原受体T细胞疗法的回顾性比较
Blood Cancer J. 2020 Oct 19;10(10):105. doi: 10.1038/s41408-020-00371-6.
5
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment.双特异性CD19/CD22嵌合抗原受体T细胞治疗失败后，抗CD38嵌合抗原受体T细胞在一名复发B淋巴细胞白血病成年患者中的疗效及副作用
Cell Mol Immunol. 2020 Apr;17(4):430-432. doi: 10.1038/s41423-019-0355-5. Epub 2020 Jan 3.
6
CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.膜结合 IL-15 的 CD19 CAR-T 细胞治疗 CD19 和 CD22 CAR-T 细胞治疗失败后的 B 细胞急性淋巴细胞白血病：病例报告。
Front Immunol. 2021 Oct 7;12:728962. doi: 10.3389/fimmu.2021.728962. eCollection 2021.
7
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.异基因CD19/CD22嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病
JAMA Oncol. 2024 Jun 1;10(6):821-824. doi: 10.1001/jamaoncol.2024.0473.
8
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.CRISPR/Cas9技术构建的通用型CD19/CD22双靶点嵌合抗原受体T细胞疗法治疗复发/难治性B细胞急性淋巴细胞白血病
Clin Cancer Res. 2021 May 15;27(10):2764-2772. doi: 10.1158/1078-0432.CCR-20-3863. Epub 2021 Feb 24.
9
A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.CD22 CAR T 细胞单独或与 CD19 CAR T 细胞联合应用的系统评价和荟萃分析。
Front Immunol. 2023 Apr 27;14:1178403. doi: 10.3389/fimmu.2023.1178403. eCollection 2023.
10
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.免疫疗法耐药的急性淋巴细胞白血病细胞表现出CD19和CD22表达降低以及BTK通路依赖性。
J Clin Invest. 2024 Feb 20;134(8):e175199. doi: 10.1172/JCI175199.

引用本文的文献

1
Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies.CD19联合CD22或CD20嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤的疗效和安全性。
Front Immunol. 2025 May 13;16:1577360. doi: 10.3389/fimmu.2025.1577360. eCollection 2025.
2
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20.利妥昔单抗对费城染色体阴性急性淋巴细胞白血病CD20微小残留病清除的疗效
Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06332-y.
3
Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

本文引用的文献

1
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.商业用 tisagenlecleucel 治疗儿童和青年 B 细胞淋巴母细胞白血病后的疾病负担对结果的影响：儿科嵌合抗原受体联盟报告。
J Clin Oncol. 2022 Mar 20;40(9):945-955. doi: 10.1200/JCO.20.03585. Epub 2021 Dec 9.
2
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.嵌合抗原受体 T 细胞双重靶向 CD19 和 CD22 治疗儿童和青年复发/难治性 B 细胞急性淋巴细胞白血病患者：一项 1 期试验。
Nat Med. 2021 Oct;27(10):1797-1805. doi: 10.1038/s41591-021-01497-1. Epub 2021 Oct 12.
3
血液系统恶性肿瘤的诊疗一体化：诊断与靶向治疗的前沿进展
Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.
4
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.序贯性CD19和CD22嵌合抗原受体T细胞（CAR-T）疗法在复发/难治性成人B细胞急性淋巴细胞白血病中的显著疗效和良好安全性。
Exp Hematol Oncol. 2025 Jan 3;14(1):2. doi: 10.1186/s40164-024-00593-5.
5
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.用于治疗B细胞急性淋巴细胞白血病和B细胞非霍奇金淋巴瘤的双靶点嵌合抗原受体T细胞
Blood Adv. 2025 Feb 25;9(4):704-721. doi: 10.1182/bloodadvances.2024013586.
6
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.免疫细胞疗法治疗癌症的进展与前景
Cell Transplant. 2024 Jan-Dec;33:9636897241231892. doi: 10.1177/09636897241231892.
7
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.增强 CAR-T 细胞疗法的安全性：时空控制的合成遗传开关。
Sci Adv. 2024 Feb 23;10(8):eadj6251. doi: 10.1126/sciadv.adj6251.
8
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.儿童和青年复发/难治性B系急性淋巴细胞白血病患者在嵌合抗原受体T细胞治疗前的桥接治疗方法。
Haematologica. 2024 Dec 1;109(12):3892-3903. doi: 10.3324/haematol.2023.283780.
9
Targeting CD22 for B-cell hematologic malignancies.以CD22为靶点治疗B细胞血液系统恶性肿瘤。
Exp Hematol Oncol. 2023 Oct 11;12(1):90. doi: 10.1186/s40164-023-00454-7.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.嵌合抗原受体 T 细胞靶向 CD19 和 CD22 治疗成人复发性或难治性 B 细胞恶性肿瘤：一项 1 期试验。
Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26.
4
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.KTE-X19 抗 CD19 CAR T 细胞疗法治疗成人复发/难治性急性淋巴细胞白血病：ZUMA-3 期 1 期结果。
Blood. 2021 Jul 8;138(1):11-22. doi: 10.1182/blood.2020009098.
5
Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.抗 CD19 嵌合抗原受体 T 细胞治疗复发或难治性急性淋巴细胞白血病患者后的免疫重建动力学。
Int J Lab Hematol. 2021 Apr;43(2):250-258. doi: 10.1111/ijlh.13375. Epub 2020 Oct 28.
6
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.双特异性抗 CD20、抗 CD19 CAR T 细胞治疗复发 B 细胞恶性肿瘤：1 期剂量递增和扩展试验。
Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5.
7
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.CAR19/22 T 细胞鸡尾酒疗法治疗难治/复发性 B 细胞恶性肿瘤患者的疗效和安全性。
Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.
8
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.在治疗费城染色体阴性 B 细胞急性淋巴细胞白血病的成人患者中，早期达到可测量残留病阴性是生存的有力预测因素。
Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.
9
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.造血干细胞移植治疗成人急性淋巴细胞白血病：美国移植和细胞治疗学会 2019 年更新的循证综述。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22.
10
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).成人费城染色体阴性急性淋巴细胞白血病缓解期造血干细胞移植：欧洲成人急性淋巴细胞白血病工作组（EWALL）和欧洲血液和骨髓移植学会急性白血病工作组（EBMT）的立场声明。
Bone Marrow Transplant. 2019 Jun;54(6):798-809. doi: 10.1038/s41409-018-0373-4. Epub 2018 Nov 1.